RNA-binding protein, RNA regulatory protein, PUF family protein (Pumilio and FBF family), Post-transcriptional regulator
01
Overview
Pumilio RNA-binding protein 1 (PUM1) is a highly conserved member of the PUF family of RNA-binding proteins. It binds specific sequence motifs ("UGUA") within the 3′ untranslated regions of target mRNAs, regulating their stability, decay, and translation. PUM1 affects embryogenesis, cell development, stem cell self-renewal, and proper differentiation. It is mechanistically integral to cell cycle progression, genome stability, and responses to cellular stress. Dysregulation or mutation of PUM1 is implicated in cancer, neurological disorders such as spinocerebellar ataxia, and abnormal hematopoiesis. Its molecular structure features a signature Pumilio homology domain composed of eight repeats conferring RNA sequence specificity. Therapeutic targeting is in the exploratory stage, with no approved drugs currently.
Drugs (hypothetical/future) would interfere with RNA binding or modulation of mRNA decay/translation, altering cell-cycle regulation or stem cell maintenance. Experimental modulation could use antisense oligonucleotides, small molecules, or engineered proteins that block/prevent PUM1 interaction with target mRNAs.
03
Biological functions
Post-transcriptional regulation of gene expression by binding 3′ untranslated regions (UTRs) of target mRNAsTranslational repression and activation of specific mRNAsPromotion of mRNA decay (deadenylation and decapping)Regulation of cell cycle progression and genome stabilityMaintenance of stem cell proliferation, pluripotency, and differentiationModulation of processes such as embryogenesis, hematopoiesis, erythropoiesis, and neuronal functionRegulation of immune responses
04
Disease associations
Cancer (promotes tumor cell proliferation, invasion, and immune escape; altered expression in pancreatic, gastric, and hematologic cancers like AML)Neurodegeneration (associated with spinocerebellar ataxia and neuronal integrity disorders)Other proliferative diseasesAbnormal erythropoiesis (e.g., hemoglobin switching)Disorders related to genome instability (e.g., DICER1 syndrome)Preeclampsia and developmental syndromes
05
Safety considerations
Therapeutic targeting may risk genome instability, impaired neuronal integrity, defective hematopoiesis, or altered immune responses due to PUM1's central and multifaceted regulatory roles.Potential developmental and tissue-specific adverse effects if systemically modulated
06
Interacting drugs
None currently established; PUM1 is an emerging target with no approved drugs or chemical probes directly modulating it yet
07
Biomarkers
PUM1 itself is sometimes used as a housekeeping gene reference in gene expression studiesNo established clinical biomarkers for patient selection or efficacy monitoring for therapies targeting PUM1 as of 2024
Beyond the preview
Go deeper on Pumilio RNA-binding protein 1 (PUM1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pumilio RNA-binding protein 1 (PUM1).